Diagnosis and treatment of CD20 negative B cell lymphomas

被引：25
|
作者：
Katchi, Tasleem
Liu, Delong [1 ]
机构：
[1] New York Med Coll, Div Hematol & Oncol, Valhalla, NY 10595 USA
来源：
BIOMARKER RESEARCH | 2017年 / 5卷
关键词：
DOSE-ADJUSTED EPOCH; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BRUTON TYROSINE KINASE; CODOX-M/IVAC; BURKITT-LYMPHOMA; PHASE-II; HODGKINS-LYMPHOMA; POOR-PROGNOSIS; FOLLOW-UP;
D O I：
10.1186/s40364-017-0088-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20-negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman's disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Diagnosis and treatment of CD20 negative B cell lymphomas
    Tasleem Katchi
    Delong Liu
    Biomarker Research, 5
  • [2] PAX5 immunostaining in the diagnosis of relapsed CD20 negative B-cell non Hodgkins lymphomas after treatment with rituximab
    Narbaitz, M. I.
    Kitagawa, R. B.
    Martin, C. A.
    HISTOPATHOLOGY, 2010, 57 : 152 - 152
  • [3] THE DIAGNOSTIC CHALLENGE OF RITUXIMAB-INDUCED CD20 NEGATIVE B-CELL LYMPHOMAS
    Risser, J.
    Breen, C.
    Feder, S.
    O'Leary, E.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2011, 38 (01) : 159 - 159
  • [4] The predictive significance of CD20 expression in B-cell lymphomas
    Prevodnik, Veronika Kloboves
    Lavrencak, Jaka
    Horvat, Mateja
    Novakovic, Barbara Jezersek
    DIAGNOSTIC PATHOLOGY, 2011, 6
  • [5] The predictive significance of CD20 expression in B-cell lymphomas
    Veronika Kloboves Prevodnik
    Jaka Lavrenčak
    Mateja Horvat
    Barbara Jezeršek Novakovič
    Diagnostic Pathology, 6
  • [6] Analysis of CD20 alone could be misleading in lineage determination of B-cell lymphomas: a case of CD20 negative diffuse large B-cell lymphoma in abdominal effusion
    Hoeller, S.
    Tzankov, A.
    Feichter, G.
    Obermann, E.
    Dirnhofer, S.
    CYTOPATHOLOGY, 2009, 20 (04) : 273 - 274
  • [7] Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
    Yi, Jun Ho
    BLOOD RESEARCH, 2021, 56 : 1 - 4
  • [8] Quantitative measurement of CD20 expression in chronic B-cell leukemias and lymphomas
    Huh, YO
    Keating, MJ
    Jilani, I
    Lerner, S
    Albitar, M
    CYTOMETRY, 2000, 42 (05): : 317 - 317
  • [9] Modulation of CD20 expression in B-cell lymphomas treated with rituximab.
    Seliem, RM
    Freeman, JK
    Hasserjian, RP
    BLOOD, 2002, 100 (11) : 311B - 311B
  • [10] Restoration of rituximab sensitivity in CD20 negative B-Cell lymphoma, cells; Epigenetic change of CD20 expression after treatment of rituximab.
    Tomita, Akihiro
    Hiraga, Junji
    Kiyoi, Hitoshi
    Kinoshita, Tomohiro
    Naoe, Tornoki
    BLOOD, 2006, 108 (11) : 155B - 155B
12345